Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aquestive Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aquestive Therapeutics's regulatory disclosures and financial reporting.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Aquestive Therapeutics, Inc. common stock. BlackRock reports beneficial ownership of 7,992,647 shares, representing 6.4% of the outstanding common stock.
BlackRock has sole voting power over 7,885,637 shares and sole dispositive power over 7,992,647 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than 5% of the outstanding common shares.
Daniel Barber, President and CEO of Aquestive Therapeutics, sold a total of 25,000 shares of common stock in open-market or private transactions on July 15–16, 2026, at prices between $4.00 and $4.04 per share, under a Rule 10b5-1 trading plan, and now directly holds 610,574 shares.
Daniel R. Barber submitted a notice relating to Aquestive Therapeutics (AQST) common stock, indicating an intention to sell 25,000 shares through Morgan Stanley Smith Barney LLC on or after 07/15/2026 on NASDAQ. These shares trace to 25,000 Restricted Stock Units acquired from the issuer on 03/09/2024. Over the prior three months, transactions labeled as 10b5-1 Sales show sales of 25,000 shares on 06/15/2026 and 8,257 shares on 05/15/2026, for amounts of 104010.00 and 35413.45, respectively.
Aquestive Therapeutics filed a resale prospectus registering 230,271 shares of Common Stock (the “Warrant Shares”) for resale by selling stockholders under a shelf registration. The Warrant Shares are issuable upon exercise of warrants issued in connection with a Tranche A term loan; the warrants are exercisable beginning May 12, 2026 and expire May 12, 2031.
The warrants carry an exercise price of $4.18 per share (Tranche A VWAP) and include a 4.99% beneficial ownership limitation (9.99% possible after notice and a 61-day delay). Aquestive is not selling any shares here and will only receive cash proceeds if warrants are exercised for cash; cashless exercises yield no proceeds to the company.
Aquestive Therapeutics files a resale prospectus registering up to 230,271 shares of Common Stock (the “Warrant Shares”) for resale by selling stockholders. The Warrant Shares are issuable upon exercise of warrants issued in connection with a $55.0M Tranche A term loan under a credit facility of up to $150.0M. The warrants have an exercise price of $4.18 per share (the Tranche A VWAP), became exercisable on May 12, 2026 and expire on May 12, 2031. Holders may elect cash or cashless exercise; the Company will receive cash proceeds only on cash exercises. The warrants include a Beneficial Ownership Limitation of 4.99% (or 9.99% if elected, effective 61 days after notice). The prospectus registers resale by multiple Oaktree-related selling stockholders and notes 125,466,988 shares outstanding as of June 18, 2026.
Aquestive Therapeutics director Julie Krop exercised and sold company stock under a pre-set trading plan. On June 23, 2026, she exercised options for 25,000 shares of common stock at $0.7132 per share, then sold 25,000 shares at an average price of $5.0157 in an open-market transaction.
Both the option exercise and the sale were carried out pursuant to a previously adopted Rule 10b5-1 trading plan. Following these transactions, the filing shows 0 shares of common stock held directly and no remaining listed derivative positions.
Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 25,000 shares of common stock. The shares were sold at a weighted average price of $4.1604 per share, within a range from $4.14 to $4.235 per share.
After this transaction, Barber directly holds 635,574 shares of Aquestive Therapeutics common stock.
AQST submitted a Form 144 reporting the proposed sale of 25,000 restricted stock units originally granted on 03/09/2024. The filing also discloses a Rule 10b5-1 sale by Daniel R. Barber of 8,257 common shares on 05/15/2026 for $35,413.45.